DEXCOM INC — Director's Dealing 2017

Nov 30, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: DEXCOM INC (DXCM)
CIK: 0001093557
Period of Report: 2017-11-29

Reporting Person: Balo Andrew K (EVP, Reg. Strategy, Clinical)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-11-29	Common Stock	S	6490	$60.0	Disposed	82792	Direct

Footnotes

F1: On December 09, 2016, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan.

F2: Included in this number are 55,678 unvested restricted stock units, 28,761 of which were granted on March 8, 2017 and shall vest through March 8, 2020, 19,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019 and 7,917 of which were granted on March 8, 2015 and shall vest through March 8, 2018.